Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar ...

The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.

💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular events by 14% in people with type 2 diabetes and heart or kidney disease. ️ The ...

This growing global health crisis calls for effective obesity treatments to reduce the burden on healthcare systems. Semaglutide, the weekly injectable drug better known by its brand names Ozempic and ...

Studies show promising results for semaglutide as a potential treatment for alcohol use disorder. Semaglutide, a GLP-1 drug, was initially used for type 2 diabetes treatment and weight loss.

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a ...